1  0.036 (3.73%)		10-06 16:00
Open: 1.07 High: 1.1 Volume: 11,000,463		Pre. Close: 0.964 Low: 0.97 Market Cap: 69(M)

Short term
Mid term
Targets	6-month :	1.42	1-year :	1.63
Resists	First :	1.21	Second :	1.39
Pivot price	1.02
Supports	First :	0.92	Second :	0.77
MAs	MA(5) :	0.99	MA(20) :	1.02
	MA(100) :	0.99	MA(250) :	1.03
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	13.7	D(3) :	15.3
RSI	RSI(14): 48.4
52-week	High :	1.65	Low :	0.47

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ICCM ] has closed above bottom band by 30.6%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.1 - 1.11	1.11 - 1.11
Low:	0.96 - 0.96	0.96 - 0.97
Close:	0.99 - 1	1 - 1.01

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Tue, 07 Oct 2025
ICCM: HC Wainwright & Co. Boosts Price Target to $2.50, Maintains Buy Rating | ICCM Stock News - GuruFocus

Mon, 06 Oct 2025
ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment - Yahoo Finance

Sat, 04 Oct 2025
IceCure Medical Surges on FDA Authorization for Breast Cancer Treatment - StocksToTrade

Fri, 03 Oct 2025
Icecure Medical stock surges after FDA approves breast cancer treatment - Investing.com

Fri, 03 Oct 2025
46K U.S. Women Eligible: IceCure's ProSense Receives FDA Marketing Authorization for Women ≥70 - Stock Titan

Fri, 03 Oct 2025
46,000 U.S. Women: IceCure Receives FDA Marketing Authorization for ProSense®; CPT III Covers $3,800 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	69 (M)
Shares Float	35 (M)
Held by Insiders	40.5 (%)
Held by Institutions	0.3 (%)
Shares Short	577 (K)
Shares Short P.Month	756 (K)

EPS	-0.28
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.05
Profit Margin	0 %
Operating Margin	-644.8 %
Return on Assets (ttm)	-76.5 %
Return on Equity (ttm)	-230.9 %
Qtrly Rev. Growth	-48.1 %
Gross Profit (p.s.)	0.01
Sales Per Share	0.04
EBITDA (p.s.)	-0.23
Qtrly Earnings Growth	0 %
Operating Cash Flow	-14 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-3.71
PEG Ratio	0
Price to Book value	20
Price to Sales	24.71
Price to Cash Flow	-4.86

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.